AbbVie’s 2021 Form 10-K outlines a range of organizational measures and disclosures that, while not labeled explicitly as “resilience,” describe the company’s ability to absorb strain and preserve functioning under adverse conditions. In the face of public health outbreaks, epidemics or pandemics such as COVID-19, AbbVie modified its business practices by instituting remote work, closely managing manufacturing and supply-chain resources globally to help ensure that patients continue to receive an uninterrupted supply of their medicines and monitoring clinical trial sites to protect the safety of study participants and staff. The company maintains business interruption insurance and establishes allowances for credit losses on receivables, as well as accruals for rebates, chargebacks, cash discounts and product returns, based on historical experience, inventory levels in the distribution channel and applicable pricing terms, and regularly monitors and adjusts these reserves to mitigate financial risk. AbbVie acknowledges critical dependencies on single-source suppliers and third-party service providers, which reduce its direct oversight of manufacturing processes and require ongoing legal, regulatory and performance monitoring to avoid interruptions. Its reliance on sophisticated information technology and complex software applications is similarly managed through continuous investment in data protection, system monitoring and contingency planning to guard against disruptions, data privacy breaches or breakdowns that could impair revenue or reputation. Following the acquisition of Allergan, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization, including severance and employee benefit programs and realization of targeted annual cost synergies, supported by a $4 billion revolving credit facility, term loan refinancing and active credit-rating management to preserve financial flexibility. Contingent consideration liabilities arising from business combinations are revalued at each reporting date using probability-weighted models that incorporate estimates of future sales, discount rates and milestone achievement probabilities. Collaborative, licensing and in-process R&D arrangements include milestone-based payments tied to development, regulatory or commercial milestones, reflecting a dynamic resource-deployment strategy. Debt obligations and dividend policies are managed to ensure sufficient cash flow from operations for interest payments, capital expenditures, share repurchases and shareholder returns, while pension and other post-employment benefit plans are funded and modeled using actuarial assumptions to maintain system integrity under market fluctuations. Collectively, these risk mitigation, resource allocation, operational continuity and financial management practices demonstrate AbbVie’s systemic approach to maintaining integrity and performance under internal and external pressures.